Search Results - "Staton, B A"

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors by Saltz, L B, Kanowitz, J, Kemeny, N E, Schaaf, L, Spriggs, D, Staton, B A, Berkery, R, Steger, C, Eng, M, Dietz, A, Locker, P, Kelsen, D P

“…To determine the maximum-tolerable dose (MTD) of fluorouracil (5FU) when given with fixed doses of leucovorin and irinotecan (CPT-11), to define the…”
Get more information

PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson’s Disease by Nichols, N.F, Cimini, M.G, Haas, J.V, Staton, B.A, Tedroff, J, Svensson, K.A

“…PNU-96391A is a weak dopamine (DA) D 2 receptor antagonist with behavioral stabilizing properties. Previous experiments revealed that PNU-96391A antagonizes…”
Get full text

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors by DRENGLER, R. L, KUHN, J. G, ELFRING, G. L, LOCKER, P. K, MILLER, L. L, VON HOFF, D. D, ROTHENBERG, M. L, SCHAAF, L. J, RODRIGUEZ, G. I, VILLALONA-CALERO, M. A, HAMMOND, L. A, STEPHENSON, J. A, HODGES, S, KRAYNAK, M. A, STATON, B. A

“…We conducted a phase I dose-escalation trial of orally administered irinotecan (CPT-11) to characterize the maximum-tolerated dose (MTD), dose-limiting…”
Get full text

Is Reduced Cell Size the Mechanism for Shrinkage of the Adrenal Zona Reticularis in Aging? by Staton, B. A., Mixon, R. L., Dharia, S., Brissie, R. M., Parker, C. Richard

“…In aging humans, corticosteroid production is preserved, or even increased, but there is an unexplained reduction in adrenal androgen secretion that likely has…”
Get full text

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma by Staton, B.A., Johnson, M.G., Friis, J.M., Adams, W.J.

“…A method for the determination of a bisheteroarylpiperazine, non-nucleoside HIV-1 reverse transcriptase inhibitor, delavirdine, and its N-desisopropyl…”
Get full text

Single Oral Dose Safety, Tolerability, and Pharmacokinetics of PNU-96391 in Healthy Volunteers by Rodríguez, Carlos A., Azie, Nkechi E., Adams, Gregory, Donaldson, Kirsteen, Francom, Steven F., Staton, Brian A., Bombardt, Paul A.

“…The safety, tolerability, and pharmacokinetics of PNU‐96391, an orally active weak dopamine D2 receptor antagonist with modulatory properties of central…”
Get full text